Operating profit of Jiangsu Hengrui Pharmaceuticals 2015-2022
In 2022, the Chinese firm Jiangsu Hengrui Pharmaceuticals generated around 4.1 billion yuan of profit from its operations, indicating a further drop after the steady growth before 2020. The core products of Jiangsu Hengrui Medicine include anti-tumor medicines, pain-killers, and anti-infection medicines.